Publications

Our dedication to the scientific progress is reflected in our commitment to presenting at leading academic conferences and publishing high-quality, peer-reviewed research. These publications advance our understanding of complex and debilitating conditions, decoding the intricate web of biological process involved in an effort to pave the way for new treatment options.

Aging Research and Drug Discovery Meeting (ARDD)

August 26-30, 2024  |  Copenhagen, Denmark

Bezisterim Effects on Biological Age, Alzheimer’s Epigenetics, and Neurologic Assessments

View PDF Arrow pointing to the right

Advanced Therapeutics in Movement and Related Disorders Congress® (ATMRD Congress)

June 21-25, 2024  |  Washington, D.C.

Improvement of Motor and Non-Motor Symptoms with bezisterim (NE3107) Adjunctive to carbidopa/levodopa in Patients with Parkinson’s disease: A Phase 2A, Placebo-Controlled Study

View PDF Arrow pointing to the right

Assessment of bezisterim (NE3107) in Patients with Early Parkinson’s disease: A Phase 2, Placebo-Controlled, Hybrid Decentrallized Study

View PDF Arrow pointing to the right

XXIX World Congress on Parkinson’s disease and Related Disorders hosted by the International Association of Parkinsonism and Related Disorders (IAPRD)

May 19-22, 2024  |  Lisbon, Portugal

Improvement of Motor and Non-Motor Symptoms with Bezisterim Adjunctive to Carbidopa/Levodopa in Patients with Parkinson’s disease: A Phase 2A, Placebo-Controlled Study

View PDF Arrow pointing to the right

12th Annual Alzheimer's & Parkinson's Drug Development Summit

April 23-25, 2024  |  Boston, Massachusetts

Clinical Outcomes and Biomarker Findings from a Randomized, Placebo-Controlled Trial of Bezisterim in Subjects with Mild to Moderate Probable Alzheimer’s disease

View PDF Arrow pointing to the right

Clinical Outcomes and Biomarker Findings from a Randomized, Placebo-Controlled Trial of Bezisterim in Subjects with Mild to Moderate Probable Alzheimer’s disease

View PDF Arrow pointing to the right

International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2024)

March 5-9, 2024  |  Lisbon, Portugal

Clinical Outcomes from a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects with Mild to Moderate Probable Alzheimer’s disease

View PDF Arrow pointing to the right

Improvements of Non-Motor Symptoms with NE3107 Adjunctive to Carbidopa/Levodopa in Patients with Parkinson’s disease: A Phase 2a, Placebo-Controlled Study

View PDF Arrow pointing to the right

American Association for the Study of Liver Disease (AASLD)

November 10-14, 2023  |  Boston, MA

Safety and Tolerability of Continuous Infusion Terlipressin (BIV201) in Patients With Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study

View PDF Arrow pointing to the right

Clinical Trials on Alzheimer's Disease conference (CTAD)

October 24 – 27, 2023  |  Boston, MA

Oral Presentation: Clinical Outcomes From a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects With Mild to Moderate Probable Alzheimer’s disease

View PDF Arrow pointing to the right

American Neurological Association Annual Meeting

September 11-13, 2023  |  Philadelphia, PA

Metabolic Dysregulation in Probable Alzheimer’s disease

View PDF Arrow pointing to the right

International Congress of Parkinson’s Disease and Movement Disorders

August 27-31, 2023  |  Copenhagen, Denmark

Oral Presentation: Effects of NE3107 Anti-inflammatory Treatment on Motor Activity and Neurodegenerative Features of Parkinson’s disease in a Marmoset Monkey Model

View PDF Arrow pointing to the right

Oral Presentation: Effects of NE3107 Anti-inflammatory Treatment on Motor Activity and Neurodegenerative Features of Parkinson’s disease in a Marmoset Monkey Model

View PDF Arrow pointing to the right

Safety and Pharmacokinetics of Anti-Inflammatory NE3107 Treatment in Carbidopa/Levodopa-TreatedPatients With Parkinson’s disease: A Phase 2a, Double-Blind, Placebo-Controlled Study

View PDF Arrow pointing to the right

A Randomized, Phase 2a, Double-Blind, Placebo-Controlled Clinical Trial With NE3107 Adjunctive to Carbidopa/Levodopa in Patients With Parkinson’s disease

View PDF Arrow pointing to the right

Alzheimer’s Association International Conference

July 16-20, 2023  |  Amsterdam, Netherlands

Treatment-Induced Epigenetic Modifications in MCI and Probable Alzheimer’s disease

View PDF Arrow pointing to the right

83rd Scientific Sessions of the American Diabetes Association

June 23-26, 2023  |  San Diego, CA

Metabolic Dysregulation in Probable Alzheimer’s disease

View PDF Arrow pointing to the right

Metabolic Dysregultion in Probable Alzheimer’s disease

View PDF Arrow pointing to the right

The International Liver Congress (EASL)

June 21-24  |  Vienna, Austria

Safety and Efficacy of Continuous Infusion Terlipressin (BIV201) in Patients With Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study

View PDF Arrow pointing to the right

2023 World Congress on Parkison’s Disease and Related Disorders (IAPRD)

May 13-16, 2023  |  Chicago, IL

Rationale for a Potentially Pivotal Study of NE3107 in Parkinson’s disease

View PDF Arrow pointing to the right

78th Annual Scientific Convention of the Society of Biological Psychiatry (SOBP)

April 27-29, 2023  |  San Diego, CA

Effects of NE3107 on Depression and Multi-modal Outcomes in a Phase 2, Open-label Study in Patients With Cognitive Decline Due to Degenerative Dementias

View PDF Arrow pointing to the right

Effects of NE3107 on Depression and Multi-modal Outcomes in a Phase 2, Open-label Study in Patients With Cognitive Decline Due to Degenerative Dementias

View PDF Arrow pointing to the right

2023 American Academy of Neurology (AAN) Annual Meeting

April 22 – 27, 2023  |  Boston, MA

Safety, Tolerability, and Efficacy of NE3107 From a Phase 2, Double-Blind, Placebo-Controlled Study in Levodopa/Carbidopa-Treated Patients With Parkinson’s disease

View PDF Arrow pointing to the right

Multi-Modal Correlation Analyses From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline
Due to Degenerative Dementias

View PDF Arrow pointing to the right

Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias

View PDF Arrow pointing to the right

2023 International on Alzheimer's and Parkinson's Disease and Related Neurological Disorders (AD / PD) Conference

March 28 – April 2, 2023  |  Gothenburg, Sweden

Effect of NE3107 on the Pharmacokinetics Profile of Carbidopa/Levodopa in Patients With Parkinson’s disease: A Phase 2, Double-Blind, Placebo-Controlled Study

View PDF Arrow pointing to the right

Safety, Tolerability, and Efficacy of NE3107 From a Phase 2, Double-Blind, Placebo-Controlled Study in Levodopa/Carbidopa-Treated Patients With Parkinson’s disease

View PDF Arrow pointing to the right

2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference

November 29 – December 2, 2022  |  San Francisco, California

Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias

View PDF Arrow pointing to the right

Biomarker Assessments From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias

View PDF Arrow pointing to the right

Neuroimaging Data From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias

View PDF Arrow pointing to the right